BioCryst to present new ORLADEYO results from APeX-P pediatric trial

BioCryst (BCRX) Pharmaceuticals announced that the company will present five abstracts featuring new clinical and real-world outcomes with oral, once-daily ORLADEYO for the prophylactic treatment of hereditary angioedema at the 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization joint congress. Included among these is a late-breaking abstract that highlights the first presentation of results from the APeX-P trial evaluating oral, once-daily ORLADEYO in pediatric patients with HAE who are 2 to less than12 years of age. The congress will take place in San Diego from February 28-March 3, 2025.